Tebentafusp for the treatment of metastatic uveal melanoma

Uveal melanoma is a rare disease; nevertheless, it is the most common primary intraocular malignancy among adults. Approximately half of affected patients will suffer from metastatic disease, mostly to the liver. No standard-of-care treatment exists for these patients. Median progression-free survival and overall survival for all types of treatment, including checkpoint inhibitors, have remained poor. However, the most recent phase III study results for tebentafusp, a member of a new-in-class molecule, are raising hopes for stage IV uveal melanoma patients. In this review, we examine the current literature, focusing on the most recent trial results for this new reagent. We evaluate the latest clinical results for tebentafusp and aim to shed light on its immunological strategy.Uveal melanoma is a rare disease but is the most common tumor of the eye among adults. In approximately half patients who have uveal melanoma, it will spread to other parts of the body, mostly to the liver. There is no standard type of therapy for these patients. So far, all existing therapies have shown poor outcomes. However, the new treatment tebentafusp has shown encouraging results in a recent clinical study. In this review, we discuss the latest study results for tebentafusp and outline how it works as a treatment for uveal melanoma.